Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Amevive

(Alefacept)

PreclinicalProtein / enzyme

Alefacept is used to treat moderate to severe plaque psoriasis, a skin condition that causes red, scaly patches. It works by suppressing the immune system's overactive response that causes psoriasis.[1] Amevive is currently being investigated across 5 indications[3], with its most advanced program in Preclinical.[1]

Amevive is one of 147 small molecule programs targeting Alopecia Areata. It is currently in Preclinical.

5

Indications

30

Total Trials

0

Active Trials

146

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alopecia AreataActive, not recruiting

Immune System DiseaseUnknown

Efficacy and SafetyCompleted

Allogeneic Hematopoietic Stem Cell TransplantationTerminated

Alopecia AreataPreclinical

Active, not recruiting

Immune System DiseasePreclinical

Unknown

Efficacy and SafetyPreclinical

Completed

Allogeneic Hematopoietic Stem Cell TransplantationPreclinical

Terminated

Competition

Competitive Landscape

242 competitors in Efficacy and Safety

#DrugCompanyPhaseTrials

Rinvoq

Savaysa

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Rapamune

PPrism Pharmaceuticals

Rilutek

AAzurity Pharmaceuticals

Kineret

SSwedish Orphan Biovitrum

UPLIZNA

HHorizon Therapeutics Ireland DAC

Ivarmacitinib

FFudan University

Becotatug Vedotin

FFudan University

Apatinib Mesylate

BBukwang Pharmaceutical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Psoriasis9 trials

A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis

Completed· Astellas logo

Astellas·Phase 3·NCT00674063·78 enrolled

A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate

Completed· Astellas logo

Astellas·Phase 3·NCT00673556·195 enrolled

Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis

Completed· Astellas logo

Astellas·Phase 4·NCT00493324·43 enrolled

Show 6 more trials

Safety and Pharmacokinetics (PK) of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis

Completed· Astellas logo

Astellas·Phase 2·NCT00808223·30 enrolled

Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type Psoriasis

Completed·WWake Forest University·Phase 4·NCT00655564·15 enrolled

Open-label Study to Evaluate Safety of Multiple Courses of IM Alefacept During Treatment of Chronic Plaque Psoriasis

Completed· Astellas logo

Astellas·Phase 3·NCT00692172·175 enrolled

Alefacept (Amevive) With or Without Narrowband UVB Treatment in Patients With Psoriasis.

Completed·MMedical University of Graz·N/A·NCT00407342·14 enrolled

Alefacept in Subjects With Chronic Plaque Psoriasis Who Failed to Respond to Anti-TNF Therapy

Terminated·JJohn Murray·Phase 4·NCT00953329·1 enrolled

Assess the Efficacy and Safety of Alefacept With Narrow Band Ultraviolet B Phototherapy (nbUVB) vs. Alefacept Alone in Chronic Plaque Psoriasis Subjects

Completed· Astellas logo

Astellas·Phase 4·NCT00658606·98 enrolled

Kidney Transplant3 trials

A Pilot Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients

Terminated·NNorthwestern University·Phase 1·NCT01163799·9 enrolled

A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients

Completed· Astellas logo

Astellas·Phase 2·NCT00543569·323 enrolled

A Study to Assess the Efficacy and Safety of Alefacept in Kidney Transplant Recipients

Completed· Astellas logo

Astellas·Phase 2·NCT00617604·218 enrolled

Chronic Graft Versus Host Disease2 trials

Alefacept for Chronic Graft Versus Host Disease

Completed·HHadassah Medical Organization·Phase 1/2·NCT00397332·20 enrolled

Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease

Terminated·—·Phase 2·NCT01226420·6 enrolled

Atopic Dermatitis2 trials

Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Severe Atopic Dermatitis

Completed·RRush University Medical Center·Phase 4·NCT00832585·5 enrolled

Open-Label,Singel Center Study of Alefacept in Patients With Atopic Dermatitis

Completed·IInsel Gruppe AG, University Hospital Bern·Phase 2·NCT00376129·10 enrolled

Psoriatic Arthritis1 trial

A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis

Completed· Astellas logo

Astellas·Phase 2·NCT00659412·185 enrolled

12 more indications

Graft Versus Host Disease1 trial

Alefacept for Prevention of Graft Versus Host Disease (GVHD)

Terminated·HHadassah Medical Organization·Phase 3·NCT00361413·26 enrolled

Allogeneic Hematopoietic Stem Cell Transplantation1 trial

Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation

Terminated·EEmory University·N/A·NCT01319851·3 enrolled

Efficacy1 trial

Study to Evaluate the Efficacy of Alefacept to Treat Palmar Plantar Pustulosis

Completed·—·Phase 2·NCT00301002·15 enrolled

Trial1 trial

Community Based Trial for AMEVIVE®

Completed· Astellas logo

Astellas·Phase 4·NCT00168753·114 enrolled

Cutaneous T-cell lymphoma1 trial

Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's Lymphoma

Completed·MMayo Clinic·Phase 1·NCT00438802·23 enrolled

Efficacy and Safety1 trial

Evaluate the Efficacy and Safety of One Course of Amevive in Taiwan Patients

Completed·UUni-Pharma·N/A·NCT00422617·40 enrolled

Pityriasis Rubra Pilaris1 trial

A Pilot Study of Alefacept for the Treatment of Pityriasis Rubra Pilaris

Terminated·JJoshua Zeichner·Phase 4·NCT00815633·1 enrolled

Tics1 trial

A Study of Pharmacokinetics and Safety of Alefacept in Caucasian and Japanese Healthy Volunteers

Completed· Astellas logo

Astellas·Phase 1·NCT00653822·75 enrolled

Aplastic Anemia1 trial

Alefacept in Patients With Relapsed/Refractory Aplastic Anemia

Terminated·TThe Cleveland Clinic·Phase 1·NCT01267643·4 enrolled

Alopecia Areata1 trial

Alefacept in Patients With Severe Scalp Alopecia Areata

Completed·UUniversity of Minnesota·N/A·NCT00167102·45 enrolled

Type 1 Diabetes1 trial

Inducing Remission in Type 1 Diabetes With Alefacept

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00965458·49 enrolled

Unspecified2 trials

Safety and Tolerability of Repeat Courses of IM Alefacept

Completed·—·Phase 4·NCT00794807·20 enrolled

Safety and Tolerability of Repeat Courses of IM Alefacept

Completed· Biogen logo

Biogen·Phase 3·NCT00233662·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 30 trial records for Alefacept. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Alefacept compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Alefacept. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Astellas company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: T-Cell Surface Antigen CD2 Inhibitor[2]
Modality: Protein / enzyme[2]
Highest Phase: Preclinical[1]
Company: Astellas

Related News